Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia01:30

Dementia

676
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
676
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment.

Journal of Alzheimer's disease : JAD·2026
Same author

Sex differences for symptoms prior to dementia onset in people with Lewy body pathology compared to pure Alzheimer's disease pathology.

Journal of Alzheimer's disease : JAD·2025
Same author

Risk factors and predictors for Lewy body dementia: a systematic review.

NPJ dementia·2025
Same author

Patterns and predictors of cholinesterase inhibitor use in dementia with Lewy bodies.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Utilization Patterns and Clinical Factors Associated With Hospitalization in Early-Stage Dementia With Lewy Bodies.

International journal of geriatric psychiatry·2025
Same author

Sex differences in prodromal dementia with Lewy bodies using the National Alzheimer's Coordinating Center data.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Acetazolamide-Responsive Exertion-Triggered Episodic Ataxia in DHDDS-Related Congenital Disorder of Glycosylation.

Movement disorders clinical practice·2026
Same journal

Epileptic-Dyskinetic Encephalopathy in Snijders Blok-Campeau Syndrome: Expanding the Phenotypic Spectrum.

Movement disorders clinical practice·2026
Same journal

Hardware Sophistications in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease; Is the Juice Worth the Squeeze?

Movement disorders clinical practice·2026
Same journal

Correction to "Advancing Neuromodulation for Functional Movement Disorders: A Contemporary Narrative Review of Evidence, Gaps, and Future Outlook".

Movement disorders clinical practice·2026
Same journal

Efficacy of IncobotulinumtoxinA (BoNT-A) Injections in Upper Limb Task-Specific and Position-Dependent Tremors.

Movement disorders clinical practice·2026
Same journal

Health-Related Quality of Life in Children with Primary Complex Motor Stereotypies.

Movement disorders clinical practice·2026
See all related articles

Related Experiment Video

Updated: Mar 28, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

DEVELOPMENT OF CLINICAL DEMENTIA RATING SCALE CUTOFF SCORES FOR PATIENTS WITH PARKINSON'S DISEASE.

Kathryn A Wyman-Chick1, B J Scott1

  • 1Pacific University School of Professional Psychology 190 SE 8 Ave Hillsboro OR 97123.

Movement Disorders Clinical Practice
|December 15, 2015
PubMed
Summary
This summary is machine-generated.

The Clinical Dementia Rating Scale (CDR) can effectively identify dementia in Parkinson's disease patients. Adjusting the scale's cutoff scores improves its accuracy for this population.

Keywords:
Parkinson's diseasecognitive screeningdementiamild cognitive impairment

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.6K

Related Experiment Videos

Last Updated: Mar 28, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.5K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.6K

Area of Science:

  • Neurology
  • Cognitive Neuroscience
  • Geriatrics

Background:

  • The Clinical Dementia Rating Scale (CDR) was developed for Alzheimer's disease.
  • Its validity for Parkinson's disease (PD) cognitive impairment is unestablished.

Purpose of the Study:

  • To evaluate the CDR scale's accuracy in measuring cognitive impairment in Parkinson's disease patients.
  • To determine if the CDR is a suitable tool for diagnosing cognitive issues in PD.

Main Methods:

  • Utilized data from 490 Parkinson's disease patients from the National Alzheimer's Coordinating Center database.
  • Calculated sensitivity, specificity, and predictive values for CDR Global Score and Sum of Boxes.
  • Employed Receiver Operating Characteristic curves to derive new, optimized cutoff scores.

Main Results:

  • Original CDR Global Score cutoffs showed low sensitivity (.34) and specificity (.10) for dementia in PD.
  • Newly calculated cutoffs demonstrated significantly improved sensitivity (.79) and specificity (.96).
  • Area under the curve (AUC) was 0.92, indicating strong diagnostic performance.

Conclusions:

  • The CDR scale is a valuable instrument for detecting dementia in Parkinson's disease.
  • Adjusting CDR cutoff scores enhances its diagnostic utility for PD-related cognitive impairment.